Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04254107 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
A Phase 1 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 133
- Enrollment target
NCT04254107: Clinical Trial Phase 1 study, sponsored by Seagen.
NCT04254107 is a Phase 1 study that was terminated before completion, run by Seagen. The registered enrollment target is 133 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (122% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04254107, a Phase 1 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 133 participants
- Enrollment target
Study Summary
This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether SEA-TGT works to treat solid tumors and lymphomas. The study will have four parts. Part A of the study will find out how much SEA-TGT should be given to patients. Part B will use the dose found in Part A to find out how safe SEA-TGT is and if it works to treat solid tumors and lymphomas. Part C will study how well SEA-TGT with sasanlimab works to treat solid tumors. Part D will study how well SEA-TGT with brentuximab vedotin works to treat classical Hodgkin lymphoma (cHL).
Primary Outcome
An AE is any untoward medical occurrence in a subject or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
Interventions
- DRUG brentuximab vedotin
- DRUG sasanlimab
- DRUG SEA-TGT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2020-05-29 |
| Est. Completion | 2023-12-01 |
| Phase | Phase 1 |
Why NCT04254107 stopped before completion
NCT04254107 is an interventional study that assigns participants to a tested intervention. The registered 133 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (122% higher).
The record links to 0 conditions, and to 3 interventions - of which brentuximab vedotin is the first listed.
NCT04254107 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04254107 about?
NCT04254107 is a clinical study titled "A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer". This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether ...
What is the current status of trial NCT04254107?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 133 participants. The study started on 2020-05-29. Estimated completion is 2023-12-01.
What interventions are being tested in trial NCT04254107?
The interventions under investigation include: brentuximab vedotin (DRUG), sasanlimab (DRUG), SEA-TGT (DRUG).
Who is sponsoring clinical trial NCT04254107?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04254107's enrollment target sits among peer trials
133 432nd of 2000 higher than 1,569 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276870 · 133 participants · Phase 2
Orphan Indications for CD19 Redirected Autologous T Cells
- NCT04671771 · 133 participants · NA
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
- NCT05610085 · 133 participants · Phase 2
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
- NCT06206486 · 133 participants
The Gut Microbiome and Serum Metabolites As a Biological Mechanism Underlying Pain in Kidney Transplantation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI